Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Parenthetical) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Total net revenue	[1]	$ 102,562	$ 99,548	$ 285,353	$ 287,951
Total cost of revenue	[2]	63,020	60,415	169,577	177,975
Research and development	[3]	13,268	11,164	37,372	37,569
Revenue from Joint Venture
Total net revenue		6,568	6,145	16,151	12,605
Total cost of revenue		2,387	4,350	7,088	8,980
Research and development		$ 0	$ 0	$ 430	$ 0

[1] Includes sales to the China joint venture, an equity method investment of $6,568 and $16,151 for the three and nine months ended March 31, 2021 and $6,145 and $12,605 for the three and nine months ended March 31, 2020, respectively. See Note 14.

[2] Includes cost of revenue from sales to the China joint venture, an equity method investment of $2,387 and $7,088 for the three and nine months ended March 31, 2021, respectively, and of $4,350 and $8,980 for the three and nine months ended March 31, 2020, respectively.

[3] Includes chargeback to the China joint venture, an equity method investment related to research and development project of $0 and $430 for the three and nine months ended March 31, 2021, respectively, and no chargeback for the three and nine months ended March 31, 2020.